SeaStar Medical

SeaStar Medical

SeaStar Medical was incorporated in 2018 before merging into a public vehicle in 2022. The firm's core asset is the Selective Cytopheretic Device (SCD), a cell-directed extracorporeal therapy that targets the disproportionate effects of systemic inflammation in critically ill patients. The SCD is designed to sequester and modulate activated neutrophils and monocytes circulating in the blood, aiming to restore balance without suppressing the broader immune system. The underlying technology emerged from research at the University of Michigan, and the company has maintained significant ties to academic investigators there. The firm's strategy centers on regulatory execution for two distinct patient populations. Its pediatric program, which targets acute kidney injury requiring continuous kidney replacement therapy, received FDA Breakthrough Device Designation and completed a pivotal study. In adults, the SCD was evaluated under an Investigational Device Exemption for acute kidney injury in the ICU. SeaStar also explored the device's application in cardiorenal syndrome and hepatorenal syndrome. In 2023, the company submitted a Humanitarian Device Exemption application to the FDA for the pediatric indication, marking its transition from clinical development toward potential first commercial launch. SeaStar Medical runs lean, with operations based in Denver, Colorado. The company went public via a special purpose acquisition company merger with LMF Acquisition Opportunities in October 2022, raising gross proceeds of roughly $15 million (per SEC filings, 2022). Subsequent financing has relied on equity lines and registered direct offerings. The firm does not operate as a family office or an investment manager; it is an operating company that deploys capital into regulatory affairs, manufacturing scale-up, and clinical evidence generation. In April 2024, the firm received FDA approval for its pediatric Humanitarian Device Exemption, triggering its first commercial product availability. The structural distinction for SeaStar Medical is its hybrid position between startup biotechnology and publicly traded medical device company. It accessed public markets prior to generating meaningful revenue, which is atypical for a medical device firm and creates distinct governance pressures. The firm's ability to navigate post-approval reimbursement, manufacturing, and commercial scale with a small capital base represents the critical execution risk that separates it from larger, established medtech peers.